News
During a live event, Mark J. Fesler, MD, and participants discussed selection and timing of initiation of JAK inhibitor ...
During a live event, Mark J. Fesler, MD, and participants discuss next steps for a 68-year-old patient with intermediate-risk myelofibrosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback